Finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, in combination with inhibitors of the renin angiotensin aldosterone system, has been shown to be effective in reducing albuminuria in patients with diabetic nephropathy (117). The gene discussed is NR3C2; the disease is diabetic kidney disease.